文献速递核素与放射性配体治疗

在小鼠前列腺癌同系模型中建立177Lu-PSMA-617放射配体治疗

Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.
PubMed 文献 · J Nucl Med · 2017-05-25

研究在同系小鼠前列腺癌模型中优化177Lu-PSMA-617放射配体治疗的比活度与总活度,发现高比活度联合120 MBq总活度可诱导DNA双链断裂、抑制肿瘤生长且无亚急性血液学毒性。

要点

  • 高比活度组的肿瘤/肾脏比值均值为19±5,高于中比活度组10±5和低比活度组2±0(每组n=3)。
  • 中或高比活度组6只小鼠中4只(67%)出现显著DNA双链断裂,低比活度组0只(0%)出现。
  • 120 MBq高比活度177Lu-PSMA-617诱导更优的肿瘤生长抑制(P=0.021,每组n=5)且无亚急性血液学毒性(每组n=3)。

核心结论

  • 177Lu-PSMA-617(120 MBq)联合高比活度在同系小鼠前列腺癌模型中产生最高疗效。
  • 该模型将有助于研究PSMA导向放射配体治疗联合潜在协同药物治疗的效果。

研究设计与样本

  • 将表达人前列腺特异性膜抗原(PSMA)的小鼠重构致癌基因驱动前列腺癌细胞(RM1,0.1×10^6)注射到C57Bl6免疫 competent小鼠左侧腹侧。
  • 通过单次尾静脉注射给予不同配方的177Lu-PSMA-617,固定比活度60 MBq(高比活度62 MBq/nmol、中比活度31 MBq/nmol、低比活度15 MBq/nmol)或固定总活度(30、60或120 MBq)。
  • 通过离体γ计数器测量确定器官分布,使用抗gamma-H2A.X(phospho S139)免疫组化测量DNA双链断裂。
  • 通过系列CT肿瘤体积测量和18F-FDG PET代谢体积评估疗效,在放射配体治疗开始后4周评估毒性。

主要发现

  • 高、中、低比活度组(每组n=3)的平均肿瘤/肾脏比值±SEM分别为19±5、10±5和2±0。
  • 中或高比活度组6只小鼠中4只(67%)出现显著DNA双链断裂(≥5% gamma-H2A.X阳性细胞),低比活度或配方组6只中0只(0%)出现。
  • 高比活度组与中或低比活度组相比,组织病理学显示更低的平均肿瘤负荷±SEM(存活组织,4±2 vs. 8±3 mm2;n=3 vs. 6)。
  • 高比活度组与中或低比活度组相比,第4天18F-FDG PET代谢体积±SEM更低(87±23 vs. 118±14 mm3;n=6 vs. 12)。
  • 高比活度组与中或低比活度组相比,第7天CT肿瘤体积±SEM更低(323±122 vs. 590±46 mm3;n=3 vs. 6;P=0.039)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer. However, to the best of our knowledge murine models to study the biologic effects of various activity levels have not been established. The aim of this study was to optimize specific and total activity for 177Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer. Methods: Murine-reconstituted, oncogene-driven prostate cancer cells (0.1 × 106) (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected into the left flank of C57Bl6 immunocompetent mice. RLT was performed by administering a single tail vein injection of 177Lu-PSMA-617 at different formulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, or 120 MBq). Organ distribution was determined by ex vivo γ-counter measurement. DNA double-strand breaks were measured using anti-gamma-H2A.X (phospho S139) immunohistochemistry. Efficacy was assessed by serial CT tumor volumetry and 18F-FDG PET metabolic volume. Toxicity was evaluated 4 wk after the start of RLT. Results: Mean tumor-to-kidney ratios ± SEM were 19 ± 5, 10 ± 5, and 2 ± 0 for high, intermediate, and low (each n = 3) specific activity, respectively. Four of 6 (67%) mice treated with intermediate or high specific activity and none of 6 (0%) mice treated with low specific activity or formulation demonstrated significant DNA double-strand breaks (≥5% γ-H2A.X-positive cells). High when compared with intermediate or low specific activity resulted in a lower mean ± SEM tumor load by histopathology (vital tissue, 4 ± 2 vs. 8 ± 3 mm2; n = 3 vs. 6), day-4 18F-FDG PET (metabolic volume, 87 ± 23 vs. 118 ± 14 mm3; n = 6 vs. 12), and day-7 CT (volume, 323 ± 122 vs. 590 ± 46 mm3; n = 3 vs. 6; P = 0.039). 177Lu-PSMA-617 (120 MBq) with high specific activity induced superior tumor growth inhibition (P = 0.021, n = 5/group) without subacute hematologic toxicity (n = 3/group). Conclusion:177Lu-PSMA-617 (120 MBq) and high specific activity resulted in the highest efficacy in a syngeneic model of murine prostate cancer. The model will be useful for studying the effects of PSMA-directed RLT combined with potentially synergistic pharmacologic approaches.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fendler WP, Stuparu AD, Evans-Axelsson S, et al. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. J Nucl Med. 2017. PMID: 28546332. doi:10.2967/jnumed.117.193359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。